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A functional fluorescent neurokinin NK2 receptor was
constructed by joining enhanced green fluorescent pro-
tein to the amino-terminal end of the rat NK2 receptor
and was expressed in human embryonic kidney cells. On
cell suspensions, the binding of fluorescent Bodipy-la-
beled neurokinin A results in a saturatable and revers-
ible decrease of NK2 receptor fluorescence via fluores-
cence resonance energy transfer. This can be quantified
for nM to mM agonist concentrations and monitored in
parallel with intracellular calcium responses. On single
cells, receptor site occupancy and local agonist concen-
tration can be determined in real time from the decrease
in receptor fluorescence. Simultaneous measurement of
intracellular calcium responses and agonist binding re-
veals that partial receptor site occupancy is sufficient to
desensitize cellular response to a second agonist appli-
cation to the same membrane area. Subsequent stimu-
lation of a distal membrane area leads to a second re-
sponse to agonist, provided that it had not been exposed
to agonist during the first application. Together with
persistent translocation of fluorescent protein kinase C
to the membrane area exposed to agonist, the present
data support that not only homologous desensitization
but also heterologous desensitization of NK2 receptors
is compartmentalized to discrete membrane domains.
Neurotransmitters stimulate target cells upon interacting
with two major categories of regulatory proteins, ligand-gated
ion channels (1–3), and G protein-coupled receptors (4). For
ligand-gated ion channels, response activation and termination
are mediated by a single molecule that carries the neurotrans-
mitter site and the effector site (1). In contrast, responses
mediated by G protein-coupled receptors result from a complex
cascade of transient and sequential interactions between the
receptor and a series of distinct messengers and effector pro-
teins, which belong to distinct subcellular compartments (5–9).
Tachykinins or neurokinins form a family of related neu-
ropeptides found throughout central and peripheral nervous
tissues. Their biological activities related to pain transmission
(10, 11), smooth muscle contraction, vasodilation, or neuro-
genic inflammation are mediated by at least three distinct G
protein-coupled receptors, NK1, NK2, and NK3, that show
preferential binding for the endogenous agonists substance P,
neurokinin A (NKA),1 and neurokinin B (NKB), respectively (12).
All three receptor isotypes belong to the family of seven trans-
membrane regulatory proteins and are coupled to an intracellu-
lar calcium release response primarily mediated by the pertussis
toxin-insensitive heterotrimeric GTP-binding protein Gq/G11.
In the present work, we have used fluorescence resonance
energy transfer-based detection of neurokinin A binding to its
G protein-coupled receptor, the NK2 tachykinin receptor, to
detect real-time interactions on living cells and to study the
spatial distribution of response activation and desensitization
at the single cell level. Tachykinin NK2 receptors were fluores-
cently labeled at the amino-terminal end with EGFP and ex-
pressed as functional membrane-bound receptors in HEK 293
cells. The binding of the natural neuropeptide neurokinin A
chemically labeled with the fluorophore Bodipy 530/550 can be
monitored by fluorescence resonance energy transfer and quan-
tified both on cell suspensions and single cells. Real time ligand
binding with high spatial resolution was measured in single
cells, thereby permitting investigation of the relationships be-
tween the distribution of receptor activation/desensitization
and cellular responses.
EXPERIMENTAL PROCEDURES
cDNA Constructs, Expression, and Selection—Rat NK2R cDNA (56)
was provided by Prof. S. Nakanishi (Kyoto University), a7-5HT3 cDNA
(57) in KS vector was provided by Prof. J. P. Changeux (Institut Pas-
teur, Paris, France), PKCa-EGFP in pEGFP-C1 vector was obtained
from Dr. D. Joubert (INSERM U469, Montpellier, France). The a7-
5HT3 sequence was excised from the plasmid by the restriction en-
zymes BsrGI and XhoI leaving the a7 signal sequence (NotI-BsrGI
fragment) linked to the KS vector. EGFP (pEGFP-C3, CLONTECH)
was mutated to introduce an additional BsrGI site (Sculptor site-di-
rected mutagenesis kit, Amersham Pharmacia Biotech) on its transla-
tion initiation codon and cloned in frame with the signal sequence as a
BsrGI-XhoI fragment (KS-sp-EGFP). NK2R cDNA in vector SK was
subcloned in vector KS between the SpeI (59-end) and XhoI (39-end)
sites. The large XhoI fragment was then cloned in the XhoI site of
KS-sp-EGFP to yield chimera 1. Chimera 2 was obtained after intro-
ducing an XhoI site on nucleotide 99 of the NK2R coding sequence, to
permit in frame fusion with EGFP. All constructs were then ligated in
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the expression vector pCEP4 (Invitrogen) between the NotI and XhoI
sites for expression in HEK 293 cells.
HEK 293 cells, grown in minimal essential medium complemented
with 10% fetal calf serum and antibiotics, were transfected by calcium
phosphate precipitation (58) and selected with 500 or 4000 mg/ml hy-
gromycin B.
Radioligand Binding Experiments—All peptides used were obtained
from Bachem. [3H]SR48968 (Amersham Pharmacia Biotech) binding
was performed on intact cells (25,000 cells/500 ml) in Hepes buffer
(137.5 mM NaCl, 1.25 mM MgCl2, 1.25 mM CaCl2, 6 mM KCl, 5.6 mM
glucose, 10 mM Hepes, 0.4 mM NaH2PO4, 1% mM bovine serum albumin
(w/v), pH 7.4) supplemented with protease inhibitors (Complete TM,
Roche Molecular Biochemicals) at 4 °C for 2 h. Samples were filtered
through GF/C filters preincubated with 1% (w/v) milk powder in phos-
phate-buffered saline (137.5 mM NaCl, 2.68 mM KCl, 8.06 mM Na2HPO4,
1.47 mM KH2PO4) and rinsed twice with phosphate-buffered saline.
Competition experiments were performed with 0.5–1 nM [3H]SR48968,
and experimental IC50 values were converted to Ki values using the
Cheng and Prusoff relation (59). SR48968 was kindly given by Dr.
Emonds-Alt (60). For inhibition of [125I]NKA binding experiments, Ki
values were determined by taking KD 5 1 nM for NKA (14).
Synthesis of Fluorescent NKA—All reactants are dissolved in di-
methylformamide. Neurokinin A (0.2 mmol) was mixed with 0.4 mmol of
iodoacetyl-Bodipy 530/550 (Molecular Probes) and 0.8 mmol of triethyl-
amine. The volume was adjusted to 100 ml with dimethylformamide,
stirred, and allowed to stand at room temperature for 16 h. The reaction
mixture was then applied to a reverse phase high pressure liquid
chromatography column (Zorbax Z5C8 25F) equilibrated with 90% A
(0.1% trifluoroacetic acid in H2O) 10% solvent B (0.1% trifluoroacetic
acid in acetonitrile) and eluted at 1 ml/min using a 10–95% gradient of
solvent B in 60 min. Elution was monitored by optical absorption at 219
and 530 nm. The product eluting at 34 min, which exhibits strong
absorption at both wavelength, was collected, concentrated, and char-
acterized as the mono-Bodipy 530/550 derivative of neurokinin A (des-
ignated NKA-Bo) by spectrofluorimetry and by electron-spray mass
spectrometry (calculated molecular mass 1630 Daltons, determined
1629.55).
Fluorescence Measurements—All fluorescence measurements from
cell suspensions were made on a Fluorolog (SPEX) spectrofluorimeter
equipped with a 450 watt Xe lamp, a double grating excitation mono-
chromator, and a single grating emission monochromator. Slits were set
to 4 or 6 mm yielding bandwidths of 7.2 or 10.8 nm at excitation and
14.4 and 21.6 nm at emission. Data were acquired with a photon
counting photomultiplier (linear up to 107 counts/sec). Unless otherwise
stated, cell suspensions (106 cell/ml) were placed in a 1-ml cuvette with
magnetic stirring and maintained at 21 °C in a thermostatted cuvette
handler. Time-based recordings were typically sampled every 100 or
300 ms.
For intracellular calcium release responses, cells were loaded in
culture medium supplemented with 5 mM Fura-2 AM (acetylmethyl-
ester), or Fura-Red AM for 30 min at 37 °C followed by a 15-min
incubation in probe-free medium. Measurements were made in Hepes
buffer with protease inhibitors at 21 °C. Fluorescence emission was
detected at 510 nm (excitation 340 nm) for Fura-2, and at 610 nm
(excitation 488 nm) for Fura-Red.
Estimation of Donor-Acceptor Separation—E, the efficiency of energy
transfer, and Ro, the distance at which energy transfer from the donor
(EGFP) to the acceptor (Bodipy) is half-maximal, were estimated as
described previously (61). Ro is given by the equation: Ro 5 (J K2 Qo
n24)1/6 3 9.7 3 103 Å, where K2 is taken as 2/3 and n as 1.4. The
quantum yield Qo 5 0.66 of EGFP is taken from the literature (35).
From the calculated overlap integral for the combined emission of
EGFP and absorbance of Bodipy (J 5 3.14 3 10213 cm3 M21), the Ro
value was estimated to be 52.6 Å for NKA-Bo. Donor-acceptor separa-
tion is given by r 5 [(E21) 2 1]1/6 Ro, where E, the maximal efficiency
of energy transfer, given by E 5 1 - (FDA/FD), was determined by
measuring specific donor fluorescence emission in the presence (FDA)
and absence (FD) of ligand at saturating concentrations (100 nM) of
NKA-Bo. Specific EGFP fluorescence in the absence (FD) and presence
(FDA) of ligand was determined by subtracting autofluorescence of non-
transfected cells from total fluorescence of chimera 1 expressing cells
(after selection with 0.5 mg/ml hygromycin, 40% of total initial fluores-
cence is due to cell autofluorescence).
Single Cell Recordings and Confocal Microscopy—NKA-Bo binding
and intracellular calcium responses were measured from adherent
HEK cells grown on glass coverslips and incubated in Ringer solution
(140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 2 mM CaCl2, 10 mM Hepes, 11
mM glucose, pH 7.3) at room temperature in the dark, using an inverted
microscope (Nikon Eclipse TE300) equipped with a confocal imaging
system (Bio-Rad MRC 1024 ES). Cells were first loaded with Fura-
Red-AM (5 mM) for 30 min at 37 °C followed by a 15-min washout of the
probe. Images were taken with a Plan Apo 40x oil immersion objective
(Nikon). Excitation light (488 nm) was obtained using 1 or 3% power
from a 30-milliwatt Kr-Ar laser. Emitted fluorescence was recorded at
522 6 15 nm and 605 6 22 nm and was color coded (256 gray levels).
Images were acquired from a section located 3–6 mm above the glass
coverslip at 2–4 Hz and analyzed using Bio-Rad time course software.
Agonist was locally applied using pressurized (10 kilopascal) puffer
pipettes (1–2 mm diameter) positioned 2–6 mm from the cell. Unless
otherwise stated, the puffer pipette contained 200 nM NKA-Bo.
RESULTS
Construction of Fluorescent Chimeric NK2 Receptors and
Neurokinin A—Site-directed mutagenesis and ligand binding
studies of NK2 tachykinin receptors (13, 14), as well as pho-
toaffinity labeling of NK1 receptors using p-benzoyl-p-phenyl-
alanine-substance P (15, 16), have provided strong support to
the notion that tachykinins bind to extracellular domains of
their respective receptor isotypes (17). To detect the interaction
of neurokinin A with the NK2 receptor by fluorescence reso-
nance energy transfer, we prepared two complementary DNA
constructs joining the carboxyl terminus of EGFP to the hydro-
philic amino-terminal part of the NK2 receptor at positions 15
(chimera 1) and 33 (chimera 2). As EGFP is not secreted by
cells and according to the known extracellular location of the
amino-terminal end of G protein-coupled receptors, the amino-
terminal end of EGFP was further fused to the first 31 residues
of the nicotinic receptor a7 subunit (18) comprising a signal
peptide to promote translocation of the amino-terminal domain
to the extracellular space.
Neurokinin A was chemically derivatized by reaction of the
amino group of its amino-terminal histidine residue with the
fluorescent group Bodipy 530/550 iodoacetate, to yield a fluo-
rescent mono-derivative, NKA-Bo. From the overlap between
the absorbance spectrum of the Bodipy group and the emission
spectrum of EGFP a theoretical Ro value of 52.6 Å was calcu-
lated. Energy transfer is thus expected to occur with more than
10% efficiency if the Bodipy group linked to NKA, and EGFP
linked to the NK2 receptor are separated by 35–75 Å.
On transfection into HEK 293 cells, cDNAs encoding chi-
mera 1 and 2 lead to the expression of fluorescent proteins
exhibiting the characteristic excitation and emission spectra of
EGFP. However, only chimera 1 yielded surface 125I-labeled
neurokinin A binding sites sensitive to the competitive antag-
onist SR48968 (not shown) and was therefore used in further
studies.
On confocal micrographs, chimera 1 decorates plasma mem-
branes in HEK 293 cells (Fig. 1A). After incubation of the cells
with 10 mM neurokinin A for 30 min at 37 °C, spots of intense
fluorescence are detected at the plasma membrane, as well as
on each confocal cross-section through the cell (Fig. 1B),
strongly suggesting that receptor capping and internalization
takes place after agonist exposure. On the other hand, prein-
cubation with 10 mM of the competitive antagonist SR48968
results in a chimera 1 fluorescence distribution comparable to
that of control (Fig. 1C).
Functional and Pharmacological Properties of Fluorescent
Chimera 1—As shown in Fig. 1D, the addition of 10 nM NKA or
10 nM NKA-Bo to chimera 1 expressing HEK 293 cells loaded
with the calcium indicator Fura-2 results in a typical intracel-
lular calcium elevation response. These responses are not de-
tected from nontransfected cells and are blocked by preincuba-
tion with the NK2-selective nonpeptide antagonist SR48968 (1
mM; Fig. 1D) as well as by the peptide antagonists cyclo(Gln-
Trp-Phe-Gly-Leu-Met) (5 mM) or MEN-10,376 (10 mM).
Equilibrium binding studies reveal that [3H]SR48968 inter-
acts with saturatable binding sites on cells expressing either
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WT receptor or chimera 1 (Fig. 1E). Fusion of the NK2R with
EGFP does not affect [3H]SR48968 affinity (WT, KD 5 0.92 6
0.13 nM; chimera 1, KD 5 0.98 6 0.17 nM) nor the number of
chimera 1 sites (Bmax 5 0.1 pmol/25,000 cells, about 2 3 10
6
receptors expressed/cell) as compared with WT NK2 receptor
(Bmax 5 0.08 pmol/25,000 cells).
Inhibition of [3H]SR48968 binding to WT receptor and chi-
mera 1 (Fig. 1F) by the agonist NKA (WT, Ki 5 64 6 10 nM;
chimera 1, Ki 5 64 6 25 nM; n 5 3) or by the antagonist peptide
MEN-10,376 (WT, Ki 5 53 6 18 nM, n 5 3; chimera 1, Ki 5 62 6
32 nM, n 5 3; not shown) also indicates that fusion of EGFP to
the NK2 receptor does not significantly alter its pharmacolog-
ical properties. Inhibition of [3H]SR48968 binding to WT NK2R
and chimera 1 by the fluorescent neurokinin A derivative,
NKA-Bo, again reveals no difference between the two receptors
(WT, KiNKA-Bo 5 19.0 6 3.5 nM; chimera 1, KiNKA-Bo 5 16.6 6
5.7 nM, n 5 3, data not shown) and shows that NKA-Bo exhibits
about 3-fold higher equilibrium affinity than NKA.
When tested for competition against [125I]NKA binding, both
NKA and NKA-Bo exhibit higher apparent affinity (chimera 1,
KiNKA 5 1.5 6 0.5 nM; chimera 1, KiNKA-Bo 5 1.0 6 0.7 nM) than
when tested in competition against [3H]SR48968, as has been
described on cells expressing WT NK2 receptors (14). Thus,
both the fluorescent NK2 receptor and the fluorescent neuro-
kinin A derivative exhibit pharmacological and functional
properties practically identical to those of their unmodified
counterparts and therefore validate attempts to detect their
interaction via fluorescence resonance energy transfer.
Detection and Quantification of Receptor-Ligand Interactions
by Fluorescence Resonance Energy Transfer on Living Cells—
Fluorescence resonance energy transfer experiments were car-
ried out by exciting a cell suspension at the EGFP excitation
wavelength (460–470 nm) and measuring either reduction of
EGFP emission (at 510 nm) or an increase of emission of the
Bodipy group (at 550 nm) (Fig. 2A). As illustrated in Fig. 2B,
the addition of 23 or 46 nM NKA-Bo to a suspension of 106
cells/ml expressing chimera 1 results in a progressive decrease
in EGFP emission (at 510 nm) and a progressive increase in
Bodipy emission (at 550 nm). Further addition of an excess of
unlabeled NKA (10 mM), of SR48968 (20 mM), or MEN-10,376
(20 mM) fully restores EGFP emission to its initial level and
partially reduces emission at the wavelength of the Bodipy
group (Fig. 2C).
To ascertain that the observed fluorescence changes are be-
cause of energy transfer, the excitation spectrum of the donor
was recorded at the emission of the acceptor. Indeed, excitation
spectra (410–530 nm) monitored at Bodipy emission (570 nm)
in the presence of 23 nM NKA-Bo and in the presence of 23 nM
NKA-Bo together with 10 mM SR48968 allowed the determina-
tion of a subtraction excitation spectrum (Fig. 2D), which su-
perimposes well with the excitation spectrum of EGFP directly
recorded at EGFP emission (550 nm) in the absence of any
ligand. This experiment thus strongly supports that both re-
duction of EGFP emission and increase of NKA-Bo emission
signals (Fig. 2C) are because of fluorescence resonance energy
transfer.
Reduction of chimera 1 emission amplitude at 510 6 22 nm
is proportional to the concentration of added NKA-Bo. Fig. 3A
shows that in a continuous recording mode, the amplitude of
EGFP emission decrease reaches a plateau value for ligand
concentrations beyond 60 nM. When excitation is set to 460 6
11 nm, the maximal decrease of fluorescence is close to 30% of
total fluorescence (Fig. 3A) for cells selected with 0.5 mg/ml
hygromycin B. Maximal extinction was 40% when excitation
was set to 470 6 10 nm (Fig. 2C). A plot of chimera 1 emission
amplitude changes versus NKA-Bo concentration (Fig. 3B)
yields a binding curve that is best fit with a single category of
sites (nH 5 1.0 6 0.1) and an apparent KD value of 8.85 6 1.02
nM (n 5 8). This value is intermediate compared with the
apparent affinities determined by competition against [3H]SR
FIG. 1. Expression and pharmacological characterization of chimera 1. A–C, fluorescence confocal micrographs showing a section
through the middle of formaldehyde-fixed HEK 293 cells stably expressing chimera 1, in the absence of ligand (A), after a 30-min incubation at
37 °C with 10 mM NKA (B), or 10 mM SR48968 and 10 mM NKA (C). EGFP fluorescence (white signal) was detected using the excitation and emission
filters for fluorescein. Scale bars represent 10 mm. D, intracellular calcium release response recorded from Fura-2-loaded HEK 293 cells expressing
chimera 1 stimulated with 10 nM NKA (continuous lines) or 10 nM NKA-Bo (broken line). Responses were recorded at 510 nm with excitation at
340 nm. NKA response evoked from chimera 1 expressing cells was blocked by SR48968. Fluorescence is expressed as counts/sec (3 1027). E,
[3H]SR48968 binding (in dpm 3 1023) to WT NK2 (filled symbols) and chimera 1 (open symbols) expressing cells in suspension. Nonspecific binding
was determined in the presence of 10 mM NKA. Each point is the mean 6 S.D. of three independent determinations done in duplicate. F, inhibition
of [3H]SR48968 binding to WT NK2 (filled symbols) and chimera 1 (open symbols) expressing cells by SR48968 and NKA. Each point is the
normalized mean 6 S.D. of three independent determinations done in duplicate.
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48968 and [125I]NKA and presumably reflects binding of
NKA-Bo to two conformations of the receptor.
When NKA-Bo concentration is set to its apparent KD value,
NKA and SR48968 inhibit NKA-Bo binding to chimera 1 (Fig.
3C) with apparent inhibition constant values of 27.7 6 6.0 nM
(n 5 5) and 1.7 6 0.1 nM (n 5 5), respectively.
Sensitivity of Ligand-Receptor Complex Detection—Steady-
state receptor-ligand interactions were typically monitored in a
1-ml cuvette with irradiation and observation windows (3 3 10
mm) such that the efficacious volume of the cell suspension was
90 ml. At a standard cell concentration (106 cells/ml), the fluo-
rescence signal was thus statistically recorded from 90,000
cells. To test for detection sensitivity, the cell concentration
was decreased to 250,000 and 100,000 cells/ml. Taking the
lowest cell concentration (100,000 cells/ml) as reference, initial
chimera 1 fluorescence was found to increase by 2-fold at
250,000 cells/ml and by 8-fold at 1,000,000 cells/ml, in agree-
ment with the notion that the efficacious irradiated and re-
corded sample volume decreases because of light scattering.
However, at all cell concentrations, the addition of 60 nM
NKA-Bo caused a specific reversible 30% reduction of EGFP
emission amplitude (excitation 460 6 11 nm, data not shown).
The interaction between chimera 1 and NKA-Bo can thus be
recorded in a standard spectrofluorimeter from a minimum of
about 10,000 cells and represents a fixed proportion of total
fluorescence, thus allowing to determine the fraction of recep-
tors occupied independently of cell concentration.
Single Cell Recording of Ligand Binding and Intracellular
FIG. 2. Detection of fluorescent Bodipy-labeled NKA (NKA-Bo) interaction with chimera 1 from HEK 293 cells in suspension. A,
schematic view of a chimera 1-NKA-Bo complex with excitation and emission wavelength used for fluorescence measurements. E.T., energy
transfer. B, fluorescence emission spectrum (excitation 470 nm) of a 5 3 105 cells/ml suspension of chimera 1 expressing cells in the absence (trace
1) or presence of 23 nm (trace 2) or 46 nm (trace 3) of NKA-Bo. Fluorescence is expressed as counts/sec (cps). C, reversibility of 100 nM NKA-Bo
binding to chimera 1. Fluorescence emission spectra were sequentially recorded from a 2 3 106 cells/ml suspension of chimera 1 expressing cells
(trace 1), after 2 min incubation with 100 nM NKA-Bo (trace 2), and after a further 10-min incubation with 20 mM SR48968. D, detection of chimera
1 fluorescence excitation spectrum at NKA-Bo fluorescence emission. The continuous line corresponds to the subtraction between an excitation
spectrum recorded on a 5 3 105 cells/ml suspension incubated with 23 nM NKA-Bo and an excitation of the same preparation after further
incubation with 10 mM SR48968 recorded at 570 nm. The excitation spectrum of chimera 1 alone (broken line) recorded at 550 nm is included for
reference. Because of large amplitude differences between subtraction and control spectra, fluorescence is expressed in arbitrary units (a.u.).
FIG. 3. Pharmacological characterization of NKA-Bo binding to chimera 1 expressing HEK cells determined by fluorescence
resonance energy transfer. A, continuous recording of the reduction of chimera 1 fluorescence amplitude (510 nm) in the presence of various
concentrations of NKA-Bo. Normalized traces correspond to individual recordings of a 106 cell/ml suspension of chimera 1 expressing HEK 293 cells
excited at 460 nm. NKA-Bo concentrations (in nM) are given next to each trace. The trace recorded at 300 nM NKA-Bo is corrected for the increment
of 510 nm fluorescence resulting from Bodipy group emission. B, representative NKA-Bo binding curve to chimera 1. Each point corresponds to a
normalized single determination of the reduction of chimera 1 fluorescence amplitude, as measured in A at equilibrium, plotted as a function of
added NKA-Bo. The solid line corresponds to the best fit of the data to the empirical Hill equation derived for saturation. C, inhibition of NKA-Bo
binding to chimera 1 by SR48968 and NKA was determined on a suspension of chimera 1-expressing cells preincubated with the given
concentration of nonfluorescent ligand. After the addition of 8–10 nM NKA-Bo, fluorescence emission at 510 nm (excitation 460 nm) was
determined until equilibrium was reached. Each data point represents the mean 6 S.D. amplitude of the chimera 1 emission decrease as compared
with a control. The solid line corresponds to the best fit of the data points to the empirical Hill equation derived for competition.
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Calcium Elevation—Observation of single cell fluorescence by
confocal microscopy reveals that NKA-Bo application results in
a decrease of receptor fluorescence in a reversible manner (Fig.
4). This reduction exhibits dose dependence with NKA-Bo con-
centration and does not occur when an excess of SR48968 is
applied together with fluorescent agonist (not shown). As ob-
served on cell suspensions, saturating concentrations of fluo-
rescent agonist (200 nM-2 mM) lead to a maximal fluorescence
extinction of 37.5 6 2.5% (n 5 20, selection with 0.5 mg/ml
hygromycin B). When cells were selected with 4 mg/ml hygro-
mycin B, maximal extinction was 47.5 6 3% (n 5 10, not
shown). Quantification of fluorescence extinction thus allows to
determine the fraction of receptors occupied and as a conse-
quence the effective ligand concentration at the membrane. For
instance, for the cell shown in Fig. 4, the first ligand applica-
tion (2 mM, during 1 s) leads a 25% decrease of fluorescence,
thus to about 66% occupancy of receptor sites. From the
NKA-Bo saturation curve (Fig. 3B), the effective ligand concen-
tration at receptors can be estimated to be about 10 nM. After
application, NKA-Bo dissociates from its binding sites at a rate
(koff 5 0.016 s
21) almost identical to that determined on cell
suspensions (koff 5 0.018 s
21, not shown). The second applica-
tion (40-s pulse) results in 37% extinction of fluorescence and
reflects saturation of receptor sites.
Calcium responses were also recorded in parallel to ligand
binding. A first local NKA-Bo application (1 mM, 5 s) to the cell
shown in Fig. 5A leads to a large calcium response. Ligand
binding analysis reveals that the receptor fluorescence in the
area facing the tip of the application pipette (“east” side of the
cell) rapidly decreases by 15.5% (i.e. 40% of receptor sites are
occupied). A second application (1 mM, 5 s) of NKA-Bo to the
same location, 4.5 min after the first application, does not lead
to any detectable calcium response, although more than 50% of
receptor sites was not occupied during the first application.
Such ligand application to a given pole of a cell followed by a
second application to the same pole never led (n 5 20) to a
second calcium response.
Two approaches were used to test whether calcium release
machinery was desensitized or whether receptors were no lon-
ger able to couple to intracellular effectors. First, NKA 4–10, a
truncated, nondesensitizing version of NKA, was utilized. Suc-
cessive applications of NKA 4–10 to NK2R expressing oocytes
have been shown to trigger repetitive responses (19), whereas
NKA only led to a single response. Here, in agreement, re-
peated applications of NKA 4–10 (10 mM, 5 s) to HEK cells
expressing chimera 1 lead to repetitive intracellular calcium
elevations (Fig. 5B, n 5 5) unlike NKA (10 mM), which never
activated a second response (not shown). Second, to further
investigate the relationship between receptor site occupancy by
NKA-Bo and development of calcium responses, the duration of
perfusion pulses was reduced to 3 s to favor local application at
one pole of the cell only. Under such conditions, intracellular
calcium elevation initiates from limited ligand binding (27%
occupancy) to the north pole without detectable receptor occu-
pancy at the south pole (Fig. 6A–C). A second short application
(3 s) carried out 6 min later at the same pole resulted in no or
a negligibly small response. However, application of ligand to
the south pole of the same cell (Fig. 6, D–F) leads to a calcium
response resulting from ligand binding to 30% of the south pole
FIG. 4. NKA-Bo binding to a single chimera 1 expressing HEK
cell (selected with 0.5 mg/ml hygromycin B). The puffer pipette
contained 2 mM NKA-Bo and was positioned at about 4 mm from the top
of the cell. Application durations depicted by bars were 1 s (first) and
40 s (second). The solid line represents time course of fluorescence
intensity (in arbitrary units) from the whole plasma membrane area.
Confocal micrographs 1 and 3 were taken before first and second ap-
plications, respectively; images 2 and 4 were taken at maximal fluores-
cence extinction during each ligand application.
FIG. 5. A, simultaneous measurement of NKA-Bo binding and intra-
cellular calcium responses from a single cell (selected with 4 mg/ml
hygromycin B). Ligand binding was recorded from the indicated mem-
brane area at the east pole (E) as EGFP fluorescence decrease at 522
nm (arbitrary units, upper row of images, scale bar 2 mm), and calcium
elevation was recorded from the indicated response area (R) as Fura-
Red fluorescence decrease at 605 nm (arbitrary units, lower row of
images). The puffer pipette contained 1 mM NKA-Bo and was placed
facing the boxed membrane area at a distance of about 4 mm. NKA-Bo
was applied for 5 s at time 45 and 315 s (horizontal bars). Amplitudes
of receptor fluorescence decrease is 15% during the first ligand appli-
cation and 13% during the second ligand application, which correspond
to 40 and 35%, respectively, receptor occupancy. Note the lack of cal-
cium response to the second agonist application. B, absence of response
desensitization to successive applications of NKA 4–10. Intracellular
calcium rises in a single HEK cell expressing chimera 1 were measured
using Fura-Red (605-nm emission) after puffer applications of 10 mM
NKA 4–10 (5 s) separated by a 6-min washout. Images were taken at
the indicated times; the time course of Fura-Red fluorescence measured
from the response area is shown below.
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receptors with no detectable binding at the north pole. Further
stimulation of the cell, with either short (0.5 s, not shown) or
long (90 s) application to the same pole (Fig. 6, D–F), leads to
further receptor occupancy up to saturation (fluorescence de-
crease at south pole: 35%, corresponding to 95% receptor occu-
pancy) but with significantly reduced or undetectable calcium
responses (n 5 7) even after several minutes of delay between
applications. Taken together, these data demonstrate that the
inability of cells to respond to a second NKA-Bo application
4–6 min after the first application is not because of desensiti-
zation of the calcium release machinery but rather that it is
because of exposure of receptor sites to agonist and thus pre-
sumably to homologous and/or heterologous desensitization.
In contrast to NK1 receptors (20), NK2 receptors have not
yet been firmly shown to be regulated by G protein receptor
kinases, although indirect evidence supports this view (19).
NK2 receptors are on the other hand well known to be regu-
lated via desensitization involving activation of protein kinase
C by the second messengers calcium and diacylglycerol, pro-
duced by phospholipase C (9, 21). When HEK cells expressing
WT NK2 receptors are transfected with PKCa-EGFP, applica-
tion of NKA stimulates PKCa translocation to the plasma
membrane (Fig. 7A) and intracellular calcium elevation (Fig.
7B). Local agonist application leads to rapid and reversible
PKC translocation to the plasma membrane (as seen in Fig. 7A,
recording area 4). Analysis of the time course of PKC translo-
cation (Fig. 7C) reveals that PKC rapidly but transiently mi-
grates to the whole perimeter of the cell (areas 2–4). It then
redistributes to a longer lasting membrane-bound form that
accumulates at the pole exposed to agonist (Fig. 7A, area 4)
with a return to initial conditions within 1 min following ago-
nist application (Fig. 7C).
DISCUSSION
Since the identification of G protein-coupled neurotransmit-
ter receptors, many proteins involved in the regulation of the
responses mediated by these receptors have been identified and
their biochemical roles characterized (4, 7). It is now also well
established that stimulation of one defined receptor isotype
may trigger several response pathways, depending for instance
on the agonist (22), on the cell type (21, 23), on the dose or
duration of agonist application (24, 25), or on sequential inter-
action with intracellular effectors (26). Although several exper-
imental approaches have been developed to better understand,
in a dynamic manner, the relationships between the receptors,
their ligands, and their effectors (27–31), new tools are still
needed to improve detection sensitivity, temporal resolution,
and to allow investigation on intact cells.
The recent isolation (32), identification, structural resolution
(33, 34), and engineering of the gene encoding jellyfish
autofluorescent proteins (35), the green fluorescent protein,
and its mutants, has led to the development of new tools to
label proteins and to investigate their expression (36), traffick-
ing (37), subcellular distribution (38), homophilic or hetero-
philic interactions (39), or to monitor structural or conforma-
tional changes (40).
As a step toward developing sensitive detection methods
applicable to G protein-coupled neurotransmitter receptors, we
FIG. 6. Selective local applications of NKA-Bo and measurements of ligand binding and intracellular calcium from a single cell
(selected with 0.5 mg/ml hygromycin B). Ligand binding was recorded from the indicated (N, green line and S, blue line) membrane areas as
EGFP fluorescence decrease at 522 nm (arbitrary units, upper row of images, scale bar 2 mm), and calcium elevation was recorded from the
indicated response area (R, red line) as Fura-Red fluorescence decrease at 605 nm (arbitrary units, lower row of images). The puffer pipette
contained 200 nM NKA-Bo and was placed as indicated in the images; agonist was applied at each pole for 3 s. Because of a change of cell shape
between application at north pole and application at south pole, areas of quantification were defined for each recording, therefore accounting for
slight changes in initial fluorescence levels. A–C, agonist application at the north pole. Ligand rapidly binds to the N area and initiates a calcium
response with a 2-s delay but does not reach the S area. Images were taken 1 s before ligand application (30 s), 2 s after the beginning of perfusion
(33 s), and 9 s after the beginning of perfusion (40 s). D–F, agonist application at the south pole of the same cell 6 min after the initial application
at the north pole. Ligand binding to S pole receptors initiates a calcium response without measurable N pole receptor occupancy. A subsequent long
duration application (90 s) leads to saturation of receptor sites at the S pole and partial occupancy of sites at the N pole with a very weak calcium
response. Images were taken 1 s before (29 s) and 10 s after (40 s) the first agonist application and after saturation of receptor sites by a 90 s
application (340 s).
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use EGFP to genetically label the NK2 receptor in a quantita-
tive and homogeneous manner. EGFP was linked to the amino-
terminal end of the NK2 receptor, rather than to the carboxyl
terminus, for two reasons. First, green fluorescent protein is a
substrate of cAMP-dependent protein kinases in mammalian
cells (41), and phosphorylation of green fluorescent protein is
accompanied by a two-fold increase of fluorescence emission.
Because NK2 receptors may stimulate cAMP production, as
shown in Rat-1 cells (21), a phosphorylation-associated change
in intrinsic green fluorescent protein fluorescence may inter-
fere with the recording of the desired ligand-receptor interac-
tion signal. Second, the calculated Ro value (in the 50 Å range)
for energy transfer between EGFP and the Bodipy group indi-
cates that energy transfer can reasonably be measured be-
tween fluorophores located on the same side of the plasma
membrane. However, it is unlikely, given the size of EGFP
(50 3 30 Å) and thickness of the lipid bilayer (40–60 Å), that
efficient energy transfer will take place from one side of the
bilayer to the other.
We find that fusion of EGFP at the amino-terminal end of the
NK2 receptor is an efficient way to label the receptor without
altering its properties. Indeed, the expression level of chimera
1 is similar to that of wild type receptors, and confocal micro-
graphs confirm that the fluorescent protein is correctly tar-
geted to the plasma membrane compartment. Also, agonist-
and antagonist-binding properties, as well as coupling of the
mutant receptor to intracellular calcium responses and long
term regulation of response desensitization, are comparable, if
not identical, to those of the wild type receptor. Such absence of
changes in the pharmacological and physiological properties of
receptors may be general, as similar tagging of the human
muscarinic M1 receptor has been also found to yield a fully
functional membrane-bound protein (42, 43).
Neither EGFP nor Bodipy appear to behave as conformation-
sensitive probes in the present context. Indeed, activation of
chimera 1 with NKA is not accompanied by EGFP fluorescence
changes, and activation of WT receptor with NKA-Bo also does
not result in any fluorescence change of the Bodipy group.
Thus, EGFP and Bodipy are likely to freely reorientate, with-
out experiencing changes in their environment, in the un-
bound and bound forms of the receptor and the ligand, and
serve as conformation-independent reporters of receptor-ligand
interactions.
NKA-Bo binding is best detected and quantified by meas-
uring extinction of EGFP emission, because at the Bodipy
emission wavelength, a significant emission resulting from di-
rect excitation of Bodipy at 460–470 nm is detected. Interest-
ingly, for saturating ligand concentrations, EGFP fluorescence
extinction reaches a maximal amplitude that is reproducible
between cell batches (37% for cells selected with 0.5 mg/ml
hygromycin B and 47% at 4 mg/ml). Thus, as for cell suspen-
sions, effective ligand concentration at the membrane and re-
ceptor occupancy can be quantified on single cells. As shown
here, direct detection of receptor occupancy allows the estima-
tion of ligand diffusion and thus exposure of receptors to the
effective ligand concentration with high spatial resolution.
As previously shown with NKA (19), NKA-Bo leads to rapid
and long-lasting desensitization of cellular responses, which
contrasts with the nondesensitizing responses elicited by the
truncated neurokinin, NKA 4–10. Desensitization of NKA-Bo
responses is pronounced at membrane areas exposed to agonist
and takes place at concentrations that do not saturate receptor
sites. Homologous desensitization, i.e. desensitization of recep-
tor molecules activated by agonist, thus may not represent the
sole regulatory pathway accounting for the profound desensi-
tization to NKA-Bo.
NK2 receptors are well known to be regulated via desensiti-
zation involving protein kinase C (21). The present work shows
that PKCa translocation to the membrane is more pronounced
and lasts much longer at the pole of the cell exposed to NKA-Bo
than at the other poles. This is in agreement with observations
made on the tumor mast cell line 2H3 showing that calcium
elevation is sufficient to promote PKC translocation to the
membrane but not activation, which requires the additional
presence of diacylglycerol (9, 44). The present data further
suggest that the long lasting translocation of PKC to the
plasma membrane takes place in the vicinity of activated re-
ceptor molecules, where phospholipase C may selectively be-
come active to locally produce diacylglycerol.
Consistent with the notion of subcellular compartmentaliza-
tion of G protein-coupled receptor signal transduction regula-
tion is the finding that several effectors of G protein-coupled
receptors are localized to membrane microdomains (45–47),
where receptor molecules (48–50) associate with heterotri-
meric G proteins (51, 52), PKC isoforms (53, 54), and second
messengers such as diacylglycerol (55). In such a scheme, com-
partmentalized desensitization of tachykinin receptors may
take place in a pseudo-heterologous manner within membrane
microdomains to which active PKC would be targeted and
would phosphorylate not only agonist-bound forms of receptors
but also unliganded receptor molecules. Therefore, similar to
response activation and homologous desensitization, which
both strictly depend on exposure to agonist and exhibit com-
FIG. 7. Translocation of PKCa-EGFP after stimulation of WT
NK2 receptor expressing HEK 293 cells. A–B, PKCa fluorescence
was recorded from the indicated membrane areas as EGFP fluorescence
at 522 nm (A, arbitrary units, upper row of images) and calcium eleva-
tion was recorded from the indicated response area (1) as Fura-Red
fluorescence decrease at 605 nm (B, arbitrary units, lower row of im-
ages). The puffer pipette contained 1 mM NKA and was positioned facing
area 4 as indicated in image 1; agonist was applied for 1 s. Images
shown (scale bar 2 mm) are taken 1 s before application (11 s, applica-
tion was at 12 s) and at the indicated times after (13 s, peak of response;
14 s, beginning of PKC translocation; 32 s, concentration of PKC in area
4; 60 and 85 s, return to basal level). C, time course of changes in
PKCa-EFGP fluorescence (from membrane areas 2–4) and Fura-Red
fluorescence from the response area 1.
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partmentalization, heterologous desensitization could also de-
velop in the vicinity of activated receptors.
In conclusion, the present work shows that receptor-ligand
interactions at G protein-coupled receptors can be monitored
and quantified by fluorescence resonance energy transfer, an
approach that is compatible with live cells, and thus with
preservation of intracellular effectors of the response and as-
sociated second messengers. Such interactions can be meas-
ured with high spatial resolution and followed in parallel with
intracellular calcium response onset and decline to show com-
partmentalization not only of response activation but also of
desensitization, including heterologous desensitization. Time-
resolved measurement of ligand binding together with the
monitoring of the activation of intracellular effectors should
allow the further characterization of the pattern of interactions
regulating cellular responses mediated by G protein-coupled
receptors.
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